Home/Federal/Federal Register/2023-14690

Notice2023-14690

Request for Nominations for Individuals and Consumer Organizations for Advisory Committees

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

July 12, 2023

Issuing agencies

Health and Human Services DepartmentFood and Drug Administration

Abstract

The Food and Drug Administration (FDA or Agency) is requesting that any consumer organizations interested in participating in the selection of voting and/or nonvoting consumer representatives to serve on its advisory committees or panels notify FDA in writing. FDA is also requesting nominations for voting and/or nonvoting consumer representatives to serve on advisory committees and/or panels for which vacancies currently exist or are expected to occur in the near future. Nominees recommended to serve as a voting or nonvoting consumer representative may be self-nominated or may be nominated by a consumer organization. FDA seeks to include the views of individuals on its advisory committee regardless of their gender identification, religious affiliation, racial and ethnic identification, or disability status and, therefore, encourages nominations of appropriately qualified candidates from all groups.

Full Text

<html>
<head>
<title>Federal Register, Volume 88 Issue 132 (Wednesday, July 12, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 132 (Wednesday, July 12, 2023)]
[Notices]
[Pages 44365-44369]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-14690]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-2727]

Request for Nominations for Individuals and Consumer
Organizations for Advisory Committees

AGENCY: Food and Drug Administration, Department of Health and Human
Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is requesting
that any consumer organizations interested in participating in the
selection of voting and/or nonvoting consumer representatives to serve
on its advisory committees or panels notify FDA in writing. FDA is also
requesting nominations for voting and/or nonvoting consumer
representatives to serve on advisory committees and/or panels for which
vacancies currently exist or are expected to occur in the near future.
Nominees recommended to serve as a voting or nonvoting consumer
representative may be self-nominated or may be nominated by a consumer
organization. FDA seeks to include the views of individuals on its
advisory committee regardless of their gender identification, religious
affiliation, racial and ethnic identification, or disability status
and, therefore, encourages nominations of appropriately qualified
candidates from all groups.

DATES: Any consumer organization interested in participating in the
selection of an appropriate voting or nonvoting member to represent
consumer interests on an FDA advisory committee or panel may send a
letter or email stating that interest to FDA (see ADDRESSES) by August
28, 2023, for vacancies listed in this notice. Concurrently, nomination
materials for prospective candidates should be sent to FDA (see
ADDRESSES) by August 28, 2023. Nominations will be accepted for current
vacancies and for those that will or may occur through December 31,
2023.

ADDRESSES: All statements of interest from consumer organizations
interested in participating in the selection process should be
submitted electronically to <a href="/cdn-cgi/l/email-protection#7435373b3927270116191d07071d1b1a07341210155a1c1c075a131b02">[email&#160;protected]</a> or by mail to
Advisory Committee Oversight and Management Staff, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5122, Silver
Spring, MD 20993-0002.
Consumer representative nominations should be submitted
electronically by logging into the FDA Advisory Committee Membership
Nomination Portal: <a href="https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm">https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm</a>, or by mail to Advisory Committee Oversight and
Management Staff, 10903 New Hampshire Ave., Bldg. 32, Rm. 5122, Silver
Spring, MD 20993-0002. Additional information about becoming a member
of an FDA advisory committee can also be obtained by visiting FDA's
website at <a href="https://www.fda.gov/AdvisoryCommittees/default.htm">https://www.fda.gov/AdvisoryCommittees/default.htm</a>.

FOR FURTHER INFORMATION CONTACT: For questions relating to
participation in the selection process: Kimberly Hamilton, Advisory
Committee Oversight and Management Staff, Food and Drug Administration,
10903 New Hampshire Ave., Bldg. 32, Rm. 5122, Silver Spring, MD 20993-
0002, 301-796-8220, <a href="/cdn-cgi/l/email-protection#046f6d69666176687d2a6c65696d68706b6a446260652a6c6c772a636b72">[email&#160;protected]</a>.
For questions relating to specific advisory committees or panels,
contact the appropriate contact person listed in table 1.

Table 1--Advisory Committee Contacts
------------------------------------------------------------------------
Contact person Committee/panel
------------------------------------------------------------------------
Rakesh Raghuwanshi, Office of the Chief FDA Science Board Advisory
Scientist, Food and Drug Committee.
Administration, 10903 New Hampshire
Ave., Bldg. 1, Rm. 3309, Silver Spring,
MD 20993-0002, 301-796-4769,
<a href="/cdn-cgi/l/email-protection#83d1e2e8e6f0ebadd1e2e4ebf6f4e2edf0ebeac3e5e7e2adebebf0ade4ecf5">[email&#160;protected]</a>.
Prabhakara Atreya, Center for Biologics Allergenic Products Advisory
Evaluation and Research, Food and Drug Committee.
Administration, 10903 New Hampshire
Ave., Bldg. 71, Rm. 1226, Silver
Spring, MD 20993-0002, 240-402-8006,
<a href="/cdn-cgi/l/email-protection#57072536353f363c36253679163b2325322e3617313336793f3f2479303821">[email&#160;protected]</a>.
Moon Hee Choi, Center for Drug Anesthetic and Analgesic Drug
Evaluation and Research, Food and Drug Products Advisory Committee;
Administration, 10903 New Hampshire Non-Prescription Drugs
Ave., Bldg. 31, Rm. 2434, Silver Advisory Committee.
Spring, MD 20993-0002, 301-796-2894,
<a href="/cdn-cgi/l/email-protection#3e73515150765b5b107d5651577e585a5f1056564d10595148">[email&#160;protected]</a>.
She-Chia Jankowski, Center for Drug Antimicrobial Drugs Advisory
Evaluation and Research, Food and Drug Committee.
Administration, 10903 New Hampshire
Ave., Bldg. 31 Rm. 2438, Silver Spring,
MD 20993-0002, 240-402-5343, <a href="/cdn-cgi/l/email-protection#93c0fbf6bed0fbfaf2bdd9f2fdf8fce4e0f8fad3f5f7f2bdfbfbe0bdf4fce5">[email&#160;protected]</a>.

[[Page 44366]]

Jessica Seo, Center for Drug Evaluation Peripheral and Central Nervous
and Research, Food and Drug System Drugs Advisory
Administration, 10903 New Hampshire Committee.
Ave., Bldg. 31, Rm. 2412, Silver
Spring, MD 20993-0002, 301-796-7699,
<a href="/cdn-cgi/l/email-protection#bcf6d9cfcfd5dfdd92efd9d3fcdad8dd92d4d4cf92dbd3ca">[email&#160;protected]</a>.
Yvette Waples, Center for Drug Cardiovascular and Renal Drugs
Evaluation Research, Food and Drug Advisory Committee; Medical
Administration, 10903 New Hampshire Imaging Drugs Advisory
Ave., Bldg. 31, Rm. 2510, Silver Committee.
Spring, MD 20993-0002, 301-796-9034,
<a href="/cdn-cgi/l/email-protection#643d12011010014a330514080117240200054a0c0c174a030b12">[email&#160;protected]</a>.
LaToya Bonner, Center for Drug Endocrinologic and Metabolic
Evaluation and Research, Food and Drug Drugs Advisory Committee.
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2428, Silver
Spring, MD 20993-0002, 301-796-2855,
<a href="/cdn-cgi/l/email-protection#420e23162d3b236c002d2c2c2730022426236c2a2a316c252d34">[email&#160;protected]</a>.
Takyiah Stevenson, Center for Drug Pharmacy Compounding Advisory
Evaluation Research, Food and Drug Committee.
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2406, Silver
Spring, MD 20993-0002, 240-402-2507,
<a href="/cdn-cgi/l/email-protection#6f3b0e0416060e07413c1b0a190a011c00012f090b0e4107071c41080019">[email&#160;protected]</a>.
Joyce Frimpong, Center for Drug Psychopharmacologic Drugs
Evaluation and Research, Food and Drug Advisory Committee.
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2426, Silver
Spring, MD 20993-0002, 301-796-7973,
<a href="/cdn-cgi/l/email-protection#cb81a4b2a8aee58db9a2a6bba4a5ac8badafaae5a3a3b8e5aca4bd">[email&#160;protected]</a>.
Candace Nalls, Center for Devices and Anesthesiology and Respiratory
Radiological Health, Food and Drug Therapy Devices Panel;
Administration, 10903 New Hampshire Clinical Chemistry and
Ave., Bldg. 66, Rm. 5211, Silver Clinical Toxicology Devices
Spring, MD 20993-0002, 301-636-0510, Panel; Ear, Nose and Throat
<a href="/cdn-cgi/l/email-protection#83c0e2ede7e2e0e6adcde2efeff0c3e5e7e2adebebf0ade4ecf5">[email&#160;protected]</a>. Devices Panel;
Gastroenterology-Urology
Devices Panel; General and
Plastic Surgery Devices
Panel.
James Swink, Center for Devices and Circulatory System Devices
Radiological Health, Food and Drug Panel; Microbiology Devices
Administration, 10903 New Hampshire Panel.
Ave., Bldg. 66, Rm. 5211, Silver
Spring, MD 20993-0002, 301-796-6313,
<a href="/cdn-cgi/l/email-protection#5e143f333b2d700d293730351e383a3f7036362d70393128">[email&#160;protected]</a>.
Akinola Awojope, Center for Devices and Dental Products Panel;
Radiological Health, Food and Drug Orthopaedic and
Administration, 10903 New Hampshire Rehabilitation Devices Panel.
Ave., Bldg. 66, Rm. 5216, Silver
Spring, MD 20993-0002, 301-636-0512,
<a href="/cdn-cgi/l/email-protection#74351f1d1a1b18155a35031b1e1b0411341210155a1c1c075a131b02">[email&#160;protected]</a>.
Jarrod Collier, Center for Devices and General Hospital and Personal
Radiological Health, Food and Drug Use Devices Panel; Hematology
Administration, 10903 New Hampshire and Pathology Devices Panel;
Ave., Bldg. 71, Rm. 1333, Silver Molecular and Clinical
Spring, MD 20993-0002, 240-672-5763, Genetics Panel; Ophthalmic
<a href="/cdn-cgi/l/email-protection#d79db6a5a5b8b3f994b8bbbbbeb2a597b1b3b6f9bfbfa4f9b0b8a1">[email&#160;protected]</a>. Devices Panel; Radiological
Devices Panel.
James Swink, Center for Devices and National Mammography Quality
Radiological Health, Food and Drug Assurance Advisory Committee.
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5211, Silver
Spring, MD 20993-0002, 301-796-6313,
<a href="/cdn-cgi/l/email-protection#0248636f67712c51756b6c69426466632c6a6a712c656d74">[email&#160;protected]</a>.
------------------------------------------------------------------------

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting
and/or nonvoting consumer representatives for the vacancies listed in
table 2:

Table 2--Committee Descriptions, Type of Consumer Representative Vacancy, and Approximate Date Needed
----------------------------------------------------------------------------------------------------------------
Committee/panel/areas of expertise needed Type of vacancy Approximate date needed
----------------------------------------------------------------------------------------------------------------
FDA Science Board Advisory Committee--The 1--Voting............................. Immediately.
Science Board provides advice to the
Commissioner of Food and Drugs
Administration (Commissioner) and other
appropriate officials on specific complex
scientific and technical issues important
to FDA and its mission, including
emerging issues within the scientific
community. Additionally, the Science
Board provides advice that supports the
Agency in keeping pace with technical and
scientific developments, including in
regulatory science; and input into the
Agency's research agenda, and on
upgrading its scientific and research
facilities and training opportunities. It
also provides, where requested, expert
review of Agency-sponsored intramural and
extramural scientific research programs.
Allergenic Products Advisory Committee-- 1--Voting............................. Immediately.
Knowledgeable in the fields of allergy,
immunology, pediatrics, internal
medicine, biochemistry, and related
specialties.
Anesthetic and Analgesic Drug Products 1--Voting............................. Immediately.
Advisory Committee--Knowledgeable in the
fields of anesthesiology, analgesics
(such as: abuse deterrent opioids, novel
analgesics, and issues related to opioid
abuse), epidemiology or statistics, and
related specialties.
Non-Prescription Drugs Advisory Committee-- 1--Voting............................. Immediately.
Knowledgeable in the fields of internal
medicine, family practice, clinical
toxicology, clinical pharmacology,
pharmacy, dentistry, and related
specialties.
Antimicrobial Drugs Advisory Committee-- 1--Voting............................. Immediately.
Knowledgeable in the fields of infectious
disease, internal medicine, microbiology,
pediatrics, epidemiology or statistics,
and related specialties.
Peripheral and Central Nervous Systems 1--Voting............................. Immediately.
Drugs Advisory Committee--Knowledgeable
in the fields of neurology,
neuropharmacology, neuropathology,
otolaryngology, epidemiology or
statistics, and related specialties.
Cardiovascular and Renal Drugs Advisory 1--Voting............................. Immediately.
Committee--Knowledgeable in the fields of
cardiology, hypertension, arrhythmia,
angina, congestive heart failure,
diuresis, and biostatistics.
Medical Imaging Drugs Advisory Committee-- 1--Voting............................. Immediately.
Knowledgeable in the fields of nuclear
medicine, radiology, epidemiology,
statistics, and related specialties.
Endocrinologic and Metabolic Drugs 1--Voting............................. Immediately.
Advisory Committee--Knowledgeable in the
fields of endocrinology, metabolism,
epidemiology or statistics, and related
specialties.

[[Page 44367]]

Pharmacy Compounding Advisory Committee-- 1--Voting............................. October 1, 2023.
Knowledgeable in the fields of
pharmaceutical compounding,
pharmaceutical manufacturing, pharmacy,
medicine, and related specialties.
Psychopharmacologic Drugs Advisory 1--Voting............................. Immediately.
Committee--Knowledgeable in the fields of
psychopharmacology, psychiatry,
epidemiology or statistics, and related
specialties.
Anesthesiology and Respiratory Therapy 1--Nonvoting.......................... Immediately.
Devices Panel--Anesthesiologists,
pulmonary medicine specialists, or other
experts who have specialized interests in
ventilator support, pharmacology,
physiology, or the effects and
complications of anesthesia.
Clinical Chemistry and Clinical Toxicology 1--Nonvoting.......................... Immediately.
Devices Panel--Doctor of Medicine or
Philosophy with experience in clinical
chemistry (e.g., cardiac markers),
clinical toxicology, clinical pathology,
clinical laboratory medicine, and
endocrinology.
Ear, Nose and Throat Devices Panel-- 1--Nonvoting.......................... November 1, 2023.
Otologists, neurotologists, audiologists.
Gastroenterology-Urology Devices Panel-- 1--Nonvoting.......................... Immediately.
Gastroenterologists, urologists, and
nephrologists.
General and Plastic Surgery Devices Panel-- 1--Nonvoting.......................... Immediately.
Surgeons (general, plastic,
reconstructive, pediatric, thoracic,
abdominal, pelvic and endoscopic);
dermatologists; experts in biomaterials,
lasers, wound healing, and quality of
life; and biostatisticians.
Circulatory System Devices Panel-- 1--Nonvoting.......................... Immediately.
Interventional cardiologists,
electrophysiologists, invasive (vascular)
radiologists, vascular and cardiothoracic
surgeons, and cardiologists with special
interest in congestive heart failure.
Microbiology Devices Panel--Clinicians 1--Nonvoting.......................... Immediately.
with an expertise in infectious disease,
e.g., pulmonary disease specialists,
sexually transmitted disease specialists,
pediatric infectious disease specialists,
experts in tropical medicine and emerging
infectious diseases, mycologists;
clinical microbiologists and virologists;
clinical virology and microbiology
laboratory directors, with expertise in
clinical diagnosis and in vitro
diagnostic assays, e.g., hepatologists;
molecular biologists.
Dental Products Panel--Dentists, engineers 1--Nonvoting.......................... Immediately.
and scientists who have expertise in the
areas of dental implants, dental
materials, periodontology, tissue
engineering, and dental anatomy.
Orthopaedic and Rehabilitation Devices 1--Nonvoting.......................... Immediately.
Panel--Orthopedic surgeons (joint spine,
trauma, and pediatric); rheumatologists;
engineers (biomedical, biomaterials, and
biomechanical); experts in rehabilitation
medicine, sports medicine, and connective
tissue engineering; and biostatisticians.
General Hospital and Personal Use Devices 1--Nonvoting.......................... Immediately.
Panel--Internists, pediatricians,
neonatologists, endocrinologists,
gerontologists, nurses, biomedical
engineers, or microbiologists/infection
control practitioners or experts.
Hematology and Pathology Devices Panel-- 1--Nonvoting.......................... Immediately.
Hematologists (benign and/or malignant
hematology), hematopathologists (general
and special hematology, coagulation and
hemostasis, and hematological oncology),
gynecologists with special interests in
gynecological oncology, cytopathologists,
and molecular pathologists with special
interests in development of predictive
biomarkers.
Molecular and Clinical Genetics Devices 1--Nonvoting.......................... Immediately.
Panel--Experts in human genetics and in
the clinical management of patients with
genetic disorders, e.g., pediatricians,
obstetricians, neonatologists. The Agency
is also interested in considering
candidates with training in inborn errors
of metabolism, biochemical and/or
molecular genetics, population genetics,
epidemiology, and related statistical
training. Additionally, individuals with
experience in genetic counseling, medical
ethics, as well as ancillary fields of
study will be considered.
Ophthalmic Devices Panel--Ophthalmists 1--Nonvoting.......................... Immediately.
with expertise in corneal-external
disease, vitreo-retinal surgery,
glaucoma, ocular immunology, ocular
pathology; optometrists; vision
scientists; and ophthalmic professionals
with expertise in clinical trial design,
quality of life assessment,
electrophysiology, low vision
rehabilitation, and biostatistics.
Radiological Devices Panel--Physicians 1--Nonvoting.......................... Immediately.
with experience in general radiology,
mammography, ultrasound, magnetic
resonance, computed tomography, other
radiological subspecialties, and
radiation oncology; scientists with
experience in diagnostic devices,
radiation physics, statistical analysis,
digital imaging, and image analysis.
National Mammography Quality Assurance 3--Voting............................. Immediately.
Advisory Committee--Physician,
practitioner, or other health
professional whose clinical practice,
research specialization, or professional
expertise includes a significant focus on
mammography.
----------------------------------------------------------------------------------------------------------------

I. Functions and General Description of the Committee Duties

A. FDA Science Board Advisory Committee

The Science Board Advisory Committee (Science Board) provides
advice to the Commissioner of Food and Drugs (Commissioner) and other
appropriate officials on specific complex scientific and technical
issues important to FDA and its mission, including emerging issues
within the scientific community. Additionally, the Science Board
provides advice that supports the Agency in keeping pace with technical
and scientific developments, including in regulatory science, and input
into the Agency's research agenda and on upgrading its scientific and
research facilities and training opportunities. It also provides, where
requested, expert review of Agency-sponsored intramural and extramural
scientific research programs.

B. Allergenic Products Advisory Committee

Reviews and evaluates available data concerning the safety,
effectiveness, and adequacy of labeling of marketed and investigational
allergenic biological products or materials that are administered to
humans for the diagnosis, prevention, or treatment of

[[Page 44368]]

allergies and allergic disease and makes appropriate recommendations to
the Commissioner regarding the affirmation or revocation of biological
product licenses; on the safety, effectiveness, and labeling of the
products; on clinical and laboratory studies of such products; on
amendments or revisions to regulations governing the manufacture,
testing, and licensing of allergenic biological products; and on the
quality and relevance of FDA's research programs.

C. Anesthetic and Analgesic Drug Products Advisory Committee

Reviews and evaluates available data concerning the safety and
effectiveness of marketed and investigational human drug products
including analgesics, e.g., abuse-deterrent opioids, novel analgesics,
and issues related to opioid abuse, and those for use in anesthesiology
and makes appropriate recommendations to the Commissioner.

D. Non-Prescription Drugs Advisory Committee

Reviews and evaluates available data concerning the safety and
effectiveness of over-the-counter (non-prescription) human drug
products, or any other FDA-regulated product, for use in the treatment
of a broad spectrum of human symptoms and diseases and advises the
Commissioner either on the promulgation of monographs establishing
conditions under which these drugs are generally recognized as safe and
effective and not misbranded or on the approval of new drug
applications for such drugs. The Committee serves as a forum for the
exchange of views regarding the prescription and non-prescription
status, including switches from one status to another, of these various
drug products and combinations thereof. The Committee may also conduct
peer review of Agency-sponsored intramural and extramural scientific
biomedical programs in support of FDA's mission and regulatory
responsibilities.

E. Antimicrobial Drugs Advisory Committee

Reviews and evaluates available data concerning the safety and
effectiveness of marketed and investigational human drug products for
use in the treatment of infectious diseases and disorders.

F. Arthritis Drugs Advisory Committee

Reviews and evaluates data concerning the safety and effectiveness
of marketed and investigational human drug products for use in the
treatment of arthritis, rheumatism, and related diseases.

G. Peripheral and Central Nervous System Drugs Advisory Committee

Reviews and evaluates data concerning the safety and effectiveness
of marketed and investigational human drug products for use in the
treatment of neurologic diseases.

H. Cardiovascular and Renal Drugs Advisory Committee

Reviews and evaluates available data concerning the safety and
effectiveness of marketed and investigational human drug products for
use in the treatment of cardiovascular and renal disorders.

I. Medical Imaging Drugs Advisory Committee

Reviews and evaluates data concerning the safety and effectiveness
of marketed and investigational human drug products for use in
diagnostic and therapeutic procedures using radioactive pharmaceuticals
and contrast media used in diagnostic radiology.

J. Endocrinologic and Metabolic Drugs Advisory Committee

Reviews and evaluates data concerning the safety and effectiveness
of marketed and investigational human drug products for use in the
treatment of endocrine and metabolic disorders.

K. Pharmacy Compounding Advisory Committee

Provides advice on scientific, technical, and medical issues
concerning drug compounding under sections 503A and 503B of the Federal
Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 353a and 353b), and,
as required, any other product for which FDA has regulatory
responsibility.

L. Psychopharmacologic Drugs Advisory Committee

Reviews and evaluates data concerning the safety and effectiveness
of marketed and investigational human drug products for use in the
practice of psychiatry and related fields.

M. Medical Devices Advisory Committee Panels

The Medical Devices Advisory Committee has established certain
panels to review and evaluate data on the safety and effectiveness of
marketed and investigational devices and make recommendations for their
regulation. With the exception of the Medical Devices Dispute
Resolution Panel, each panel, according to its specialty area: (1)
advises on the classification or reclassification of devices into one
of three regulatory categories and advises on any possible risks to
health associated with the use of devices; (2) advises on formulation
of product development protocols; (3) reviews premarket approval
applications for medical devices; (4) reviews guidelines and guidance
documents; (5) recommends exemption of certain devices from the
application of portions of the FD&C Act; (6) advises on the necessity
to ban a device; and (7) responds to requests from the Agency to review
and make recommendations on specific issues or problems concerning the
safety and effectiveness of devices. Except for the Medical Devices
Dispute Resolution Panel, each panel, according to its specialty area,
may also make appropriate recommendations to the Commissioner on issues
relating to the design of clinical studies regarding the safety and
effectiveness of marketed and investigational devices.
The Medical Devices Dispute Resolution Panel provides advice to the
Commissioner on complex or contested scientific issues between FDA and
medical device sponsors, applicants, or manufacturers relating to
specific products, marketing applications, regulatory decisions and
actions by FDA, and Agency guidance and policies. The Panel makes
recommendations on issues that are lacking resolution, are highly
complex in nature, or result from challenges to regular advisory panel
proceedings or Agency decisions or actions.

N. National Mammography Quality Assurance Advisory Committee

Advises the Agency on the development of appropriate quality
standards and regulations for mammography facilities; standards and
regulations for bodies accrediting mammography facilities under this
program; regulations with respect to sanctions; procedures for
monitoring compliance with standards; establishing a mechanism to
investigate consumer complaints; reporting new developments concerning
breast imaging that should be considered in the oversight of
mammography facilities. The Committee also advises on determining
whether there exists a shortage of mammography facilities in rural and
health professional shortage areas and determining the effects of
personnel on access to the services of such facilities in such areas;
determining whether there will be a sufficient number of medical
physicists after October 1, 1999; and determining the costs and
benefits of compliance with these requirements.

[[Page 44369]]

II. Criteria for Members

Persons nominated for membership as consumer representatives on
committees or panels should meet the following criteria: (1)
demonstrate an affiliation with and/or active participation in consumer
or community-based organizations, (2) be able to analyze technical
data, (3) understand research design, (4) discuss benefits and risks,
and (5) evaluate the safety and efficacy of products under review. The
consumer representative should be able to represent the consumer
perspective on issues and actions before the advisory committee; serve
as a liaison between the committee and interested consumers,
associations, coalitions, and consumer organizations; and facilitate
dialogue with the advisory committees on scientific issues that affect
consumers.

III. Selection Procedures

Selection of members representing consumer interests is conducted
through procedures that include the use of organizations representing
the public interest and public advocacy groups. These organizations
recommend nominees for the Agency's selection. Representatives from the
consumer health branches of Federal, State, and local governments also
may participate in the selection process. Any consumer organization
interested in participating in the selection of an appropriate voting
or nonvoting member to represent consumer interests should send a
letter stating that interest to FDA (see ADDRESSES) within 30 days of
publication of this document.
Within the subsequent 45 days, FDA will compile a list of consumer
organizations that will participate in the selection process and will
forward to each such organization a ballot listing at least two
qualified nominees selected by the Agency based on the nominations
received, together with each nominee's current curriculum vitae or
r[eacute]sum[eacute]. Ballots are to be filled out and returned to FDA
within 30 days. The nominee receiving the highest number of votes
ordinarily will be selected to serve as the member representing
consumer interests for that particular advisory committee or panel.

IV. Nomination Procedures

Any interested person or organization may nominate one or more
qualified persons to represent consumer interests on the Agency's
advisory committees or panels. Self-nominations are also accepted.
Nominations must include a current, complete r[eacute]sum[eacute] or
curriculum vitae for each nominee and a signed copy of the
Acknowledgement and Consent form available at the FDA Advisory
Nomination Portal (see ADDRESSES), and a list of consumer or community-
based organizations for which the candidate can demonstrate active
participation.
Nominations must also specify the advisory committee(s) or panel(s)
for which the nominee is recommended. In addition, nominations must
also acknowledge that the nominee is aware of the nomination unless
self-nominated. FDA will ask potential candidates to provide detailed
information concerning such matters as financial holdings, employment,
and research grants and/or contracts to permit evaluation of possible
sources of conflicts of interest. Members will be invited to serve for
terms of up to 4 years.
FDA will review all nominations received within the specified
timeframes and prepare a ballot containing the names of qualified
nominees. Names not selected will remain on a list of eligible nominees
and be reviewed periodically by FDA to determine continued interest.
After selecting qualified nominees for the ballot, FDA will provide
those consumer organizations that are participating in the selection
process with the opportunity to vote on the listed nominees. Only
organizations vote in the selection process. Persons who nominate
themselves to serve as voting or nonvoting consumer representatives
will not participate in the selection process.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: July 6, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-14690 Filed 7-11-23; 8:45 am]
BILLING CODE 4164-01-P

</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on July 12, 2023.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.